Okushin K, Tateishi R, Takahashi A, et al. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol. 2022;57:587–97. https://doi.org/10.1007/s00535-022-01893-5.

Article  CAS  PubMed  Google Scholar 

Enomoto H, Akuta N, Hikita H, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. 2024;54:763–72. https://doi.org/10.1111/hepr.14047.

Article  CAS  PubMed  Google Scholar 

Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453–64. https://doi.org/10.1016/s0140-6736(18)32111-1.

Article  CAS  PubMed  Google Scholar 

Paik JM, Younossi Y, Henry L, et al. Recent trends in the global burden of hepatitis B virus: 2007–2017. Gastroenterology. 2021;160:1845-6.e3. https://doi.org/10.1053/j.gastro.2020.11.057.

Article  PubMed  Google Scholar 

Ioannou GN, Beste LA, Green PK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264-78.e4. https://doi.org/10.1053/j.gastro.2019.07.033.

Article  CAS  PubMed  Google Scholar 

Murai K, Hikita H, Yamada R, et al. The risk of developing hepatocellular carcinoma persists in chronic hepatitis B patients even after the long-term administration of nucleos(t)ide analogs. Hepatol Res. 2025;55:1228–38. https://doi.org/10.1111/hepr.14225.

Article  CAS  PubMed  Google Scholar 

Tahata Y, Sakamori R, Yamada R, et al. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. Hepatol Res. 2022;52:824–32. https://doi.org/10.1111/hepr.13806.

Article  CAS  PubMed  Google Scholar 

Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504–13. https://doi.org/10.1016/j.jhep.2016.10.028.

Article  CAS  PubMed  Google Scholar 

Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951–63. https://doi.org/10.1007/s00535-021-01796-x.

Article  PubMed  PubMed Central  Google Scholar 

Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. https://doi.org/10.1001/jamanetworkopen.2024.54707.

Article  PubMed  PubMed Central  Google Scholar 

Owrangi S, Paik JM, Golabi P, et al. Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2025;61:433–43. https://doi.org/10.1111/apt.18451.

Article  PubMed  Google Scholar 

Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56:942–56. https://doi.org/10.1111/apt.17158.

Article  CAS  PubMed  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-97.e10. https://doi.org/10.1053/j.gastro.2015.04.043.

Article  PubMed  Google Scholar 

Sakai K, Shima T, Oya H, et al. Association between liver fibrosis and cause-specific mortality in Japanese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a prospective cohort study/liver fibrosis and mortality in Japanese MASLD. Hepatol Res. 2025. https://doi.org/10.1111/hepr.70034.

Article  PubMed  Google Scholar 

Grady JT, Cyrus JW, Sterling RK. Novel noninvasive tests for liver fibrosis: moving beyond simple tests in metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2025. https://doi.org/10.1016/j.cgh.2025.02.035.

Article  PubMed  Google Scholar 

Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD practice guideline. Hepatology. 2025;81:725–48. https://doi.org/10.1097/HEP.0000000000000852.

Article  PubMed  Google Scholar 

Kumazaki S, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024;60:327–39. https://doi.org/10.1111/apt.18063.

Article  CAS  PubMed  Google Scholar 

Myojin Y, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther. 2022;55:422–33. https://doi.org/10.1111/apt.16691.

Article  CAS  PubMed  Google Scholar 

Sometani E, Hikita H, Murai K, et al. High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatol Res. 2024. https://doi.org/10.1111/hepr.14111.

Article  PubMed  Google Scholar 

Myojin Y, Hikita H, Tahata Y, et al. Serum growth differentiation factor 15 can be a novel biomarker to predict the prognosis of patients with hepatitis C virus cirrhosis after virus elimination. Hepatol Res. 2025. https://doi.org/10.1111/hepr.70041.

Article  PubMed  Google Scholar 

Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514–9. https://doi.org/10.1073/pnas.94.21.11514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lawton LN, Bonaldo MF, Jelenc PC, et al. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene. 1997;203:17–26. https://doi.org/10.1016/s0378-1119(97)00485-x.

Article  CAS  PubMed  Google Scholar 

Kang SG, Choi MJ, Jung SB, et al. Differential roles of GDF15 and FGF21 in systemic metabolic adaptation to the mitochondrial integrated stress response. iScience. 2021;24:102181. https://doi.org/10.1016/j.isci.2021.102181.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye J, Kumanova M, Hart LS, et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 2010;29:2082–96. https://doi.org/10.1038/emboj.2010.81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roybal CN, Hunsaker LA, Barbash O, et al. The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem. 2005;280:20331–9. https://doi.org/10.1074/jbc.M411275200.

Article  CAS  PubMed  Google Scholar 

Fessler E, Eckl EM, Schmitt S, et al. A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol. Nature. 2020;579:433–7. https://doi.org/10.1038/s41586-020-2076-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Wang M, Cheng A, et al. The role of host eIF2α in viral infection. Virol J. 2020;17:112. https://doi.org/10.1186/s12985-020-01362-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pakos-Zebrucka K, Koryga I, Mnich K, et al. The integrated stress response. EMBO Rep. 2016;17:1374–95. https://doi.org/10.15252/embr.201642195.

Article  CAS  PubMed